DelveInsight’s “Acute Myeloid Leukemia Pipeline Insights 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Acute Myeloid Leukemia Treatment Landscape @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight
Key Takeaways from the Acute Myeloid Leukemia Pipeline Report
Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Acute Myeloid Leukemia Clinical Trials Assessment
The Acute Myeloid Leukemia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Acute Myeloid Leukemia Pipeline Report also highlights the unmet needs with respect to the Acute Myeloid Leukemia.
Acute Myeloid Leukemia Overview
Acute myeloid leukemia (AML) is a rapidly progressing myeloid neoplasm characterized by the clonal expansion of immature myeloid-derived cells, known as blasts, in the peripheral blood and bone marrow. This expansion results in ineffective erythropoiesis and megakaryopoiesis, clinically manifesting as relatively rapid bone marrow failure compared to chronic and indolent leukemias. This leads to inadequate production of red blood cells and platelets.
Acute Myeloid Leukaemia Emerging Drugs Profile
Orca-T is an investigational allogeneic T-cell immunotherapy under evaluation for the treatment of multiple hematologic malignancies including acute leukemias and myelodysplastic syndromes. Orca-T is composed of highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from either related or unrelated matched donors. Currently, the drug is being evaluated in the Preregistration stage of its development for the treatment of Acute Myeloid Leukemia.
Bleximenib (JNJ-75276617) is an investigational, oral, small-molecule menin-KMT2A inhibitor showing promising activity against acute myeloid leukemia (AML) with KMT2A rearrangements or NPM1 mutations. It targets a key oncogenic interaction between menin and KMT2A fusion proteins, disrupting a pathway that drives leukemic cell growth in patients with KMT2Ar or NPM1m mutations. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Acute Myeloid Leukemia.
Romaciclib is a highly selective inhibitor of CDK8 and CDK19, minimizing off-target effects and enhancing therapeutic efficacy. This targeted approach disrupts key transcriptional programs essential for cancer cell survival while sparing healthy cells. Romaciclib has demonstrated a low potential for drug-drug interactions, making it a safer choice for patients undergoing multiple concurrent treatments. This reduces the likelihood of adverse interactions and supports better overall treatment outcomes. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Acute Myeloid Leukemia.
ABD-3001, is a small-molecules inhibitor of the ALDH family of enzymes that is at the initial stage of clinical development for a wide range of cancers, including acute myeloid leukemia. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Acute Myeloid Leukemia. This drug irreversibly binds to and inhibits ALDH1 and ALDH3, leading to metabolic stress and destruction of cancer stem cells. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Acute Myeloid Leukemia.
CER-1236 is an autologous chimeric engulfment receptor T cell (CER-T) which fuses external domain of TIM-4 with intracellular domains from T cells and innate immune cells including Toll-like receptor 2 (TLR2), CD28 and CD3ζ. This receptor binds TIM-4-ligand (phosphatidylserine) on tumor cells leading to phagocytosis and lysis of target cells followed by tumor antigen processing and cross-presentation to induce an adaptive immune response. CER-1236 was shown to eliminate AML cell in vitro, and in vivo in a xenograft model. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Acute Myeloid Leukemia.
PRO CAR-301 is an autologous CD33-directed CAR T cell that integrates a next-generation armor known as “SAVVY/IL-18”. It is an armored CD33-specific CAR T therapy for acute myeloid leukemia. It targets CD33, a cell surface protein expressed by mature myeloid cells and hematopoietic stems cells. This protein is expressed on over 80% of AML cells and hematopoietic stem cells which makes it an effective treatment target. Currently, the drug is being evaluated in the preclinical stage of its development for the treatment of Acute Myeloid Leukemia.
Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Acute Myeloid Leukemia Unmet Needs
The Acute Myeloid Leukemia pipeline report provides insights into
Acute Myeloid Leukemia Companies
Johnson & Johnson, Orca Biosystems, Inc., Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., Sunshine Lake Pharma, Sichuan Baili Pharmaceutical, Stemline Therapeutics, OncoVerity, Changzhou Qianhong Bio-pharma Co., Ltd., Delta-Fly Pharma, Menarini, Debiopharm International SA, Akeso Biopharma, AstraZeneca, Miltenyi Biomedicine GmbH, AB Science, Chordia Therapeutics, Molecular Partners AG, Takeda, ARCE Therapeutics, Galecto Biotech AB, Shenzhen TargetRx Co., Ltd., CRISPR Therapeutics, Lomond Therapeutics, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals and others.
The Acute Myeloid Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Acute Myeloid Leukaemia Products have been categorized under various Molecule types such as
See the latest progress in drug development and clinical research @ Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives
Scope of the Acute Myeloid Leukemia Pipeline Report
Access the Full Acute Myeloid Leukemia Pipeline Analysis Today! @ Acute Myeloid Leukemia Drugs and Companies
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insightCountry: United StatesWebsite: https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight
